Whole-brain radiation therapy in breast cancer patients with brain metastases

Nature Reviews Clinical Oncology

Volumn 7, Issue 11, 2010, Pages 632-640

  Chargari, Cyrus ^a   Campana, François ^b   Pierga, Jean Yves ^b   Védrine, Lionel ^a   Ricard, Damien ^a   Le Moulec, Sylvestre ^a   Fourquet, Alain ^b   Kirova, Youlia M ^b  

^a University of Paris Descartes   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CELECOXIB; CISPLATIN; EFAPROXIRAL; GADOLINIUM TEXAPHYRIN; LAPATINIB; NAVELBINE; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB;

BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER CONTROL; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED RADIOTHERAPY; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; GAMMA KNIFE RADIOSURGERY; HIPPOCAMPUS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KARNOFSKY PERFORMANCE STATUS; LEUKOENCEPHALOPATHY; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RADIATION RESPONSE; RADIOSENSITIZATION; REVIEW; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; WHOLE BRAIN RADIATION THERAPY;

BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; HUMANS; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 78049484896     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.119     Document Type: Review

References (89)

1. Weil, R. J., Palmieri, D. C., Bronder, J. L., Stark, A. M. & steeg, P S. Breast cancer metastasis to the central nervous system. Am. J. Pathol. 167, 913-920 (2005).
2. Bendell, J. C. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97, 2972-2977 (2003).
3. Borgelt, B. Et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat Oncol. Biol. Phys. 6, 1-9 (1980).
4. Tsao, M. N. et al. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev. 31, 256-273 (2005).
5. Wadasadawala, T., Gupta, S., Bagul, V. & Patil, N. Brain metastases from breast cancer: management approach. J. Cancer Res. Ther. 3, 157-165 (2007).
6. Patchell, R. A. The management of brain metastases. Cancer Treat Rev. 29, 533-540 (2003).
7. Patchell, R. A. et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494-500 (1990).
8. Noordijk, E. M. et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int. J. Radiat Oncol. Biol. Phys. 29, 711-717 (1994).
9. Mintz, A. H. et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78, 1470-1476 (1996).
10. Patchell, R. A. et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485-1489 (1998).
11. Suh, J. H. Stereotactic radiosurgery for the management of brain metastases. N. Engl. J. Med. 362, 1119-1127 (2010).
12. Kased, N. et al. Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int. J. Radiat Oncol. Biol. Phys. 75, 1132-1140 (2009).
13. Amendola, B. E., Wolf, A. L., Coy, S. R., Amendola, M. & Bloch, L. Gamma knife radiosurgery in the treatment of patients with single and multiple brain metastases from carcinoma of the breast. Cancer J. 6, 88-92 (2000).
14. Muacevic, A., Kreth, F. W., Tonn, J. C. & Wowra, B. Stereotactic radiosurgery for multiple brain metastases from breast carcinoma. Cancer 100, 1705-1711 (2004).
15. Chougule, P B. et al. Randomized treatment of brain metastasis with gamma knife radiosurgery wole brain radiotherapy or both [abstract]. Int. J. Radiat Oncol. Biol. Phys. 48, 114 (2000)
16. Aoyama, H. et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483-2491 (2006).
17. Mueller, R. P et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: Results of the eORTC 22952-26001 study [abstract]. J. Clin. Oncol. 27, 2008 (2009).
18. Chang, E. L. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10, 1037-1044 (2009).
19. Patel, A. J. et al. Factors influencing the risk of local recurrence after resection of a single brain metastasis. J. Neurosurg. doi:10.3171/2009. 11JNs09659.
20. Tsao, M. N. et al. Clinical practice guideline on the optimal radiotherapeutic management of brain metastases. BMC Cancer 5, 34 (2005).
21. Wong, W. W., Schild, S. E., Sawyer, T. E. & Shaw, E. G. Analysis of outcome in patients reirradiated for brain metastases. Int. J. Radiat Oncol. Biol. Phys. 34, 585-590 (1996).
22. Shaw, E. et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumours and brain metastases: final report of RTOG protocol 90-05 Int. J. Radiat Oncol. Biol. Phys. 47, 291-298 (2000).
23. Patel, R. R. & Mehta, M. P Targeted therapy for brain metastases: improving the therapeutic ratio. Clin. Cancer Res. 13, 1675-1683 (2007).
24. DeAngelis, L. M. et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 24, 798-805 (1989).
25. Ricard, D., Taillia, H. & Renard, J. L. Brain damage from anticancer treatments in adults. Curr. Opin. Oncol. 21, 559-565 (2009).
26. De Angelis, L. M., Delattre, J. Y. & Posner, J. B. Radiation-induced dementia in patients cured of brain metastases. Neurology 39, 789-796 (1989).
27. Rades, D., Lohynska, R., Veninga, T., stalpers, L. J. & schild, S. E. evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer 110, 2587-2592 (2007).
28. Gaspar, L. et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J. Radiat Oncol. Biol. Phys. 37, 745-751 (1997).
29. Weltman, E. et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int. J. Radiat Oncol. Biol. Phys. 46, 1155-1161 (2000).
30. Nieder, C., Marienhagen, K., Astner, S. T. & Molls, M. Prognostic scores in brain metastases from breast cancer. BMC Cancer 9, 105 (2009).
31. Le scodan R. et al. Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int. J. Radiat Oncol. Biol. Phys. 69. 839-845 (2007).
32. Pestalozzi, B. C. et al. Identifying breast cancer patients at risk for Central Nervous system (CNs) metastases in trials of the International Breast Cancer study Group (IBCsG). Ann. Oncol. 17, 935-944 (2006).
33. Eichler, A. F. et al. survival in patients with brain metastases from breast cancer: the importance of HeR-2 status. Cancer 112, 2359-2367 (2008).
34. Wolstenholme, V., Hawkins, M., Ashley, S., Tait, D. & Ross, G. HeR2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast 17, 661-665 (2008).
35. Niwinska, A., Murawska, M. & Pogada, K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann. Oncol. 21, 942-948 (2010).
36. Hines, S. L. et al. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen-and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann. Oncol. 19, 1561-1565 (2008).
37. Lee, S. S. et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res. Treat 111, 523-530 (2008).
38. Rades, D., Pluemer, A., Veninga, T., Dunst, J. & Schild, S. E. A boost in addition to whole-brain radiotherapy improves patient outcome after resection of 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer 110, 1551-1559 (2007).
39. Hoskin, P J., Crow, J. & Ford, H. T. The influence of extent and local management on the outcome of radiotherapy for brain metastases. Int J. Radiat Oncol. Biol. Phys. 19, 111-115 (1990).
40. Kondziolka, D., Patel, A., Lunsford, L. D., Kassam, A. & Flickinger, J. C. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J. Radiat Oncol. Biol. Phys. 45, 427-434 (1999).
41. Andrews, D. W. et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665-1672 (2004).
42. Bhatnagar, A. K., Flickinger, J. C., Kondziolka, D. & Lunsford, L. D. Stereotactic radiosurgery for four or more intracranial metastases. Int. J. Radiat Oncol. Biol. Phys. 64, 898-903 (2006).
43. Tomita, N. et al. Helical tomotherapy for brain metastases: dosimetric evaluation of treatment plans and early clinical results. Technol. Cancer Res. Treat 7, 417-424 (2008).
44. Gupta, T et al. Planning and delivery of whole brain radiation therapy with simultaneous integrated boost to brain metastases and synchronous limited-field thoracic radiotherapy using helical tomotherapy: a preliminary experience. Technol. Cancer Res. Treat 8, 15-22 (2009).
45. Sterzing, F. et al. Reirradiation of multiple brain metastases with helical tomotherapy. A multifocal simultaneous integrated boost for eight or more lesions. Strahlenther. Onkol. 185, 89-93 (2009).
46. Hsu, F. et al. Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1-3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int. J. Radiat Oncol. Biol. Phys. 76, 1480-1485 (2010).
47. Langer, C. J. & Mehta, M. P Current management of brain metastases, with a focus on systemic options. J. Clin. Oncol. 23, 6207-6219 (2005).
48. Murray, K. J. et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int. J. Radiat Oncol. Biol. Phys. 39, 571-574 (1997).
49. Monje, M. L., Mizumatsu, S., Fike, J. R. & Palmer, T. D. Irradiation induces neural precursor-cell dysfunction. Nat Med. 8, 955-962 (2002).
50. Gutiérrez, A. N. et al. Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J. Radiat Oncol. Biol. Phys. 69, 589-597 (2007).
51. Ghia, A. et al. Distribution of brain metastases in relation to the hippocampus: implications for neurocognitive functional preservation. Int. J. Radiat Oncol. Biol. Phys. 68, 971-977 (2007).
52. Soussain, C. et al. CNs complications of radiotherapy and chemotherapy. Lancet 374, 1639-1651 (2009).
53. Bauman, G. et al. Simultaneous infield boost with helical tomotherapy for patients with 1 to 3 brain metastases. Am. J. Clin. Oncol. 30, 38-44 (2007).
54. Welsh, J. S. et al. Helical tomotherapy as a means of delivering scalp-sparing whole brain radiation therapy. Technol. Cancer Res. Treat 4, 661-662 (2005).
55. Correa, D. D. & Ahles, T. A. Neurocognitive changes in cancer survivors. Cancer J. 14, 396-400 (2008).
56. Kreukels, B. P, van Dam, F. S., Ridderinkhof, K. R., Boogerd, W. & Schagen, S. B. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin. Breast Cancer 8, 80-87 (2008).
57. Rugo, H. S. & Ahles, T The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin. Oncol. 30, 749-762 (2003).
58. Viani, G. A. et al. Whole brain radiotherapy with radiosensitizer for brain metastases. J. Exp. Clin. Cancer Res. 28, 1 (2009).
59. Xu, S. et al. Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity Int. J. Radiat Oncol. Biol. Phys. 49, 1381-1390 (2001).
60. Mehta, M. P et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21, 2529-2536 (2003).
61. Amorino, G. P et al. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RsR13. Radiat Res. 156, 294-300 (2001).
62. Shaw, E. et al. RsR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J. Clin. Oncol. 21, 2364-2371 (2003).
63. Suh, J. H. et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol. 24, 106-114 (2006).
64. Scott, C., suh, J., stea, B., Nabid, A. & Hackman, J. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (efaproxyn) plus whole-brain radiation therapy for brain metastases. Am. J. Clin. Oncol. 30, 580-587 (2007).
65. Suh, J. H. et al. Results of the phase III eNRICH (RT-016) study of efaproxiral administered concurrently with whole brain radiation therapy (WBRT) in women with brain metastases from breast cancer. Int. J. Radiat Oncol. Biol. Phys. 72, s50-s51 (2008).
66. Knisely, J. P et al. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J. Radiat Oncol. Biol. Phys. 71, 79-86 (2008).
67. Eyre, H. J. et al. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment of metastatic cancer to brain. J. Neurooncol. 2, 325-330 (1984).
68. Komarnicky, L. T. et al. A randomized phase protoco for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat Oncol. Biol. Phys. 20, 53-58 (1991).
69. Phillips, T. L., Scott, C. B., Leibel, S. A., Rotman, M. & Weigensberg, I. J. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int. J. Radiat Oncol. Biol. Phys. 33, 339-348 (1995).
70. Corn, B. W. et al. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118. Int. J. Radiat Oncol. Biol. Phys. 71, 71-78 (2008).
71. Cerchietti, L. C. et al. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J. Neurooncol. 71, 73-81 (2005).
72. Cassier, P A. et al. A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. Cancer 113, 2532-2538 (2008).
73. Hedde, J. P et al. A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors. Int J. Radiat Oncol. Biol. Phys. 68, 839-844 (2007).
74. Addeo, R. et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 113, 2524-2531 (2008).
75. Addeo, R. et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and mproves quality of life. BMC Cancer 7, 18 (2007).
76. Verger, E. et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int. J. Radiat Oncol. Biol. Phys. 61, 185-191 (2005).
77. Antonadou, D. et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. 20, 3644-3650 (2002).
78. Park, Y. H. et al. Trastuzumab treatment mproves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HeR2-overexpressing breast cancer patients. Br. J. Cancer 100, 894-900 (2009).
79. Stemmler, H. J. et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HeR2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18, 23-28 (2007).
80. Liang, K. et al. Sensitization of breast cancer cells to radiation by trastuzumab. Mol. Cancer Ther. 2, 1113-1120 (2003).
81. Lin, N. U. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HeR2-positive breast cancer. Clin. Cancer Res. 15, 1452-1459 (2009).
82. Shah, N., Groom, N., Jackson, S., Sibtain, A. & Hoskin, P A Pilot study to assess the feasibility of prior scalp cooling with palliative whole brain radiotherapy. Br. J. Radiol. 73, 514-516 (2000).
83. Cuscela, D. et al. Protection from radiation-induced alopecia with topical application of nitroxides: fractionated studies. Cancer J. Sci. Am. 2, 273-278 (1996).
84. Metz, J. M. et al. A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin. Cancer Res. 10, 6411-6417 (2004).
85. Brizel, D. M. et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18, 3339-3345 (2000).
86. Nieder, C., Andratschke, N. H., Wiedenmann, N. & Molls, M. Prevention of radiation-induced central nervous system toxicity: a role for amifostine? Anticancer Res. 24, 3803-3809 (2004).
87. Lamproglou, I. et al. Radiation-induced cognitive dysfunction: the protective effect of ethyol in young rats. Int. J. Radiat Oncol. Biol. Phys. 57, 1109-1115 (2003).
88. Magné, N. et al. The efficacy and toxicity of eGFR in the settings of radiotherapy: Focus on published clinical trials. Eur. J. Cancer 44, 2133-2143 (2008).
89. Magné, N., Chargari, C., Soria, J. C. & Deutsch, E. Concomitant chemo-radiotherapy in clinical trials: to promote step by step rational development. Crit Rev. Oncol. Hematol. 70, 206-215 (2009).